Novotech, a global biotech clinical research organization and full-service CRO, has strengthened its presence in Japan with the opening of a new office in Tokyo. The new office builds on Novotech’s existing operations and clinical trial activities in Japan and is expected to strengthen the company’s ability to support Japanese biopharma companies as they expand their clinical development programmes across international markets.
The Tokyo office will serve as an important hub for Novotech’s growing business in Japan. It will provide local expertise and support closer collaboration with clients, research institutions, partners and innovation networks across the country. Novotech is already supporting clinical studies in Japan and offers sponsors access to integrated clinical development services across major markets. Its capabilities include early-phase clinical development in Australia, FDA-aligned protocol development, scientific expertise from the United States and international partnering opportunities.
Japan is one of the world’s largest pharmaceutical markets and has a strong research and healthcare ecosystem. The country’s biotechnology sector is also growing, with more Japanese biopharma companies looking to take new therapies beyond the domestic market.
The expanded Tokyo presence will help Novotech support companies conducting cross-border clinical trials and connect sponsors with clinical development opportunities across Asia-Pacific, the United States and Europe. Novotech provides clinical development support to emerging and growth-stage biotechnology and pharmaceutical companies. Its operating model is designed to help clients work across multiple regions without having to manage several separate service providers. The company has experience across a range of therapeutic areas, including oncology, rare diseases, central nervous system disorders, infectious diseases, immunology and advanced therapies.
Takeshi Mori, Country Head, Japan, said the opening of the Tokyo office marks an important milestone for Novotech. “Japan is a critical market for global clinical development, and this investment reflects our long-term commitment to building strong local capabilities while delivering high-quality services to our clients,” he said.
The new office is located at the Shinjuku i-Land Tower in Nishishinjuku, Tokyo. The opening forms part of Novotech’s broader strategy to strengthen its global presence and expand its role as a clinical research partner for biotechnology companies worldwide.
Novotech operates more than 30 offices across Asia-Pacific, North America and Europe and works with more than 7,000 clinical trial sites. The company combines local market knowledge with scientific, regulatory and operational expertise to support clinical trials and drug development programmes.
Through its global network, Novotech helps clients improve clinical trial execution, patient recruitment and data management while supporting the development of new therapies. The new Tokyo office is expected to further strengthen Novotech’s position in Japan and support the growing number of companies seeking to bring innovative healthcare solutions to patients in international markets.
